下磨牙不可逆性牙髓炎局麻药的成本效果关系:系统综述与Meta分析
该研究系统评价下磨牙症状性不可逆性牙髓炎局麻药的疗效与成本效果,纳入12项研究共1262名参与者。Meta分析显示2%利多卡因、4%阿替卡因、0.5%布比卡因和2%甲哌卡因在下牙槽神经阻滞中疗效无显著差异。含肾上腺素的2%利多卡因成本效果最优,ICER为负值。
要点
- 四种局麻药在下牙槽神经阻滞中疗效无显著差异
- 含肾上腺素2%利多卡因成本效果最优,ICER为负值
- 0.5%布比卡因虽作用时间长但成本效果最差
核心结论
- 含肾上腺素的2%利多卡因在疗效与可负担性间取得最佳平衡,为最具成本效果的局麻药选择。
- 4%阿替卡因虽组织弥散优势明确且价格较高,限制其作为常规一线用药。
研究设计与样本
- 遵循PRISMA指南的系统综述与Meta分析,已在PROSPERO注册(CRD42024615858)。
- 检索PubMed、Scopus、Web of Science、Cochrane Library、Embase和Virtual Health Library共6个数据库,检索时间为2025年1月,无限制。
- 纳入12项研究,共1262名参与者。
- 两位评价者独立提取数据并使用Cochrane RoB 2工具评估偏倚风险,采用随机效应模型进行Meta分析。
主要发现
- 2%利多卡因、4%阿替卡因、0.5%布比卡因和2%甲哌卡因在下牙槽神经阻滞中的疗效无显著差异。
- 含肾上腺素的2%利多卡因成本效果最优,呈现负的ICER值。
- 0.5%布比卡因尽管作用时间延长,但成本效果最差。
关键数值与推荐
- 成本效果由作者基于Meta分析疗效估计结合市场价格,采用增量成本效果比(ICER)评估。
- 疗效比较涉及2%利多卡因、4%阿替卡因、0.5%布比卡因和2%甲哌卡因用于下牙槽神经阻滞。
临床怎么用
- 对于下磨牙症状性不可逆性牙髓炎的下牙槽神经阻滞,含肾上腺素2%利多卡因可作为兼顾疗效与成本的首选局麻药。
- 选择4%阿替卡因时需权衡其组织弥散优势、较高成本及潜在不良反应。
局限性
- Meta分析未将阿替卡因的组织弥散优势和患者安全性作为主要结局进行量化。
- 成本效果评估由作者基于市场价格和Meta分析疗效估计完成,非原始研究直接报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This review evaluates the efficacy and cost-effectiveness of local anesthetics in managing symptomatic irreversible pulpitis in mandibular molars. METHODS: Following PRISMA guidelines, it was registered in PROSPERO (CRD42024615858). Six databases (PubMed, Scopus, Web of Science, Cochrane Library, Embase, and Virtual Health Library) were searched without restrictions in January 2025. Studies comparing the efficacy of local anesthetics for irreversible pulpitis in mandibular molars were included. Data extraction and risk of bias assessment using the Cochrane RoB 2 tool were performed independently by two reviewers. A random-effects meta-analysis was conducted. Cost-effectiveness was subsequently assessed by the authors using efficacy estimates derived from the meta-analysis combined with market prices, based on the Incremental Cost-Effectiveness Ratio (ICER). RESULTS: Twelve studies (1262 participants) were included. No significant differences in efficacy were observed among lidocaine 2%, articaine 4%, bupivacaine 0.5%, and mepivacaine 2% for inferior alveolar nerve block. Lidocaine 2% with epinephrine was the most cost-effective, presenting negative ICER values. Bupivacaine 0.5% was the least cost-effective despite its prolonged duration. CONCLUSION: Lidocaine 2% with epinephrine emerged as the most cost-effective option, offering an optimal balance between efficacy and affordability. While articaine 4% is recognized for its superior tissue diffusion, a key pharmacological advantage influencing its clinical application, and considerations of patient safety are paramount, our meta-analysis did not quantify these as primary outcomes. Nonetheless, articaine's higher cost, despite its diffusion advantages, limits its routine first-line use, and potential for adverse effects, as discussed in the literature, must always be weighed during anesthetic selection. CLINICAL RELEVANCE: This review bridges the gap between efficacy and affordability, providing clinicians with clear, evidence-based guidance for anesthetic selection in one of the most challenging endodontic scenarios.
引用
- de Carvalho LF, Dugaich APC, Schiefler AMM, et al. Is there a direct relationship between the cost and effectiveness of local anesthetics in lower molars with irreversible pulpitis? Systematic review, meta-analysis and cost-effectiveness evaluation. J Dent. 2025. PMID: 41075922. doi:10.1016/j.jdent.2025.106175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。